Unknown

Dataset Information

0

Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study.


ABSTRACT:

Background

The rate of loco-regional recurrences for locally advanced head and neck squamous cell carcinoma (HNSCC) following standard treatment reaches up to 50%, accompanied by a probability of 20% to develop a second primary tumor in the head and neck region.

Methods

Ten patients with inoperable, in-field recurrence of HNSCC following previous primary or adjuvant radiotherapy (RT) in combination with concurrent platinum-based chemotherapy were re-irradiated with 60 Gray in 30 fractions between December 2017 and January 2020 with concurrent and maintenance nivolumab administration. Data were retrospectively collected and compared with patients who underwent re-irradiation (ReRT) with concurrent cisplatin following propensity score matching (PSM). Local progression-free survival (LPFS) and overall survival (OS) were visualized using Kaplan-Meier method (log-rank test).

Results

All patients completed ReRT. Median number of applied courses of nivolumab was 12 (range, 3-38). OS rate was 50% at 12 months and the median OS was 11 (range, 2-23) months. Six and 12 month LPFS rates were 60% and 30%, respectively. Median LPFS was 8 (range, 2-19) months. OS and LPFS rates were not inferior to those of patients treated with concurrent cisplatin. No unexpected radiation-related toxicity occurred. A total of four patients developed any-grade immune-related adverse events of which two presented with grade 3 toxicities. One patient died within 3 weeks after ReRT. Higher blood levels of CRP (p = 0.004), lower levels of hemoglobin (p = 0.029) and higher neutrophil/lymphocyte ratio (p = 0.004) were associated with impaired LPFS. Higher recursive portioning analysis (RPA) class was associated with impaired LPFS (p = 0.022) and OS (p = 0.024).

Conclusion

The combination of ReRT and nivolumab for locally recurrent HNSCC was feasible without occurrence of unexpected toxicities. Combined radioimmunotherapy might offer an effective treatment option for carefully selected pre-irradiated patients ineligible for salvage surgery.

SUBMITTER: Altay-Langguth A 

PROVIDER: S-EPMC8050105 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8161822 | biostudies-literature
| S-EPMC4741508 | biostudies-literature
| S-EPMC7186263 | biostudies-literature
| S-EPMC8694210 | biostudies-literature
| S-EPMC8270105 | biostudies-literature
| S-EPMC7241232 | biostudies-literature
| S-EPMC7164259 | biostudies-literature
| S-EPMC6422429 | biostudies-literature
| S-EPMC5564292 | biostudies-literature
| S-EPMC5813741 | biostudies-literature